On October 26, the world's first inhaled recombinant novel coronavirus vaccine (type 5 adenovirus vector) developed and produced by CanSino Biologics officially started free inoculation in Shanghai. This is the first appearance of aerosol inhalation therapy into the field of vaccine applications.
In May, a clinical trial published in The Lancet proved that, as a booster shot of two inactivated vaccines, the dose of this inhaled vaccine is only one-fifth of the dose of intramuscular injection, which is safer and more immune The originality is better, and more effective antibodies are induced [1].
The vaccine uses an adenovirus vector that is harmless to the human body to deliver the genetic material expressing the S protein into the human body, and the vaccine is atomized into tiny particles by a nebulizer. , cellular triple immunity. Mucosal immunity is of great significance for the prevention of respiratory system infections. Aerosol inhalation vaccines can more efficiently induce respiratory mucosal immunity, and then play a defensive role in the first line of defense for the new coronavirus to invade the human body.
The vaccine uses an adenovirus vector that is harmless to the human body to deliver the genetic material expressing the S protein into the human body, and the vaccine is atomized into tiny particles by a nebulizer. , cellular triple immunity. Mucosal immunity is of great significance for the prevention of respiratory system infections. Aerosol inhalation vaccines can more efficiently induce respiratory mucosal immunity, and then play a defensive role in the first line of defense for the new coronavirus to invade the human body.
But at the same time, it should be noted that the target population of this vaccine is currently 18 years old and above, and it is recommended to be used with caution in those with a history of asthma, chronic obstructive pulmonary disease, pulmonary fibrosis and other underlying diseases or abnormal lung function . In terms of use, after the vaccine liquid is atomized into fine particles and injected into the atomizing cup, the vaccinator must complete a deep buccal inhalation within 15 seconds, and hold his breath for at least 5 seconds, during which time he cannot cough or exhale. It seems simple, but it has high requirements on the nebulization generating device and the nebulizing cup.
Vaccine is biological preparation, and aerosolized vaccines is more demanding than commonly used aerosolized drugs. While ensuring that the vaccines can effectively reach the lower respiratory tract, it is also necessary to keep the original activity of the vaccines from being destroyed. Moreover, the dosage of a single dose of vaccine is very small, and an nebulization generating device is required to accurately control the amount of fog and reduce residues as much as possible. At present, there are three types of nebulization generating devices on the market according to their working principles, namely ultrasonic atomizer, compression nebulizer and mesh atomizer. Due to the principle of nebulization , the working process of the first two will inevitably destroy the activity of the vaccine or have large residues, so it is recommended to use a mesh nebulizer. The atomizer used by CanSino Biologics is a mesh nebulizer.
Since CanSino Biologics took the lead in the field of aerosolized vaccines, many domestic vaccine companies are bound to follow. Feellife, as a world-renowned comprehensive solution provider of nebulization , has also launched a variety of solutions for nebulized vaccines, and customized full nebulization chain services for vaccine cooperative enterprises.
In addition to Air ICU (pictured below), a professional medical-grade aerosol vaccine solution with the same principle as the aerosol equipment shown by CanSino Biologics, FEELLIFE,
FEELLIFE provides an nebulization solution for groups such as school classes, enterprises and institutions - quantitative nebulization and inhalation AirRight equipment (as shown in the figure below),
FEELLIFE’s independent research and development has realized the precise dosing output technology, and the nebulization accuracy can reach a minimum of 10μL, which is also the world's first technology. The equipment can achieve precise inhalation of quantitative liquid medicine for each person each time, and under the one-to-many collaborative operation of professional doctors, a group of atomized inhalation therapy can be quickly and safely achieved.
The nebulizer can be connected to a spacer with a one-way valve mouthpiece for inhalation. The one-way valve can be opened when inhaling to ensure the passage of aerosols, and closed when exhaling to prevent cross infection.
In addition, FEELLIFE provides vaccinations for special populations or lighter and more convenient aerosol vaccine solutions (as shown in the figure below).
A single spark and a prairie prairie fire, FEELLIFE will join hands with vaccine companies to promote the development of the field of nebulized vaccines and build the Great Wall of National Immunization.
[1]Jing-Xin Li*, Shi-Po Wu*, Xi-Ling Guo*,Rong Tang*etc.Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.The LANCET Respiratory Medicine，VOLUME 10, ISSUE 8, P739-748, AUGUST 01, 2022